1[1]Fry W, Phillips, Menck H. Ten-year survey of lung cancer treatment and survival in hospitals in United States. Cancer,1999, 86:1867
2[2]Socinski M. Chemotherapy for stage Ⅳ non-small cell lung cancer: An evidence-based guide for the practicing clinican. Philadelphia: WB Saunders Company, 2001, 307
3[3]Ng R, Boer RD, Park A, et al. Non small cell lung cancer(NSCLC): Are elderly patients being under-treated? ASCO Pro,2004, 7118
4[4]Hensing TA, Peterman AH, Schell MJ, et al. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage ⅢB or Ⅳ nonsmall cell lung carcinoma triated with carboplatin and paclitaxel. Cancer, 2003, 98(4) :779
5[5]Lebitasy MP, Monnet L, Depierre A, et al. Management of elderly lung cancer patients in France: A national prospective survey by the French intergroup of thoracic oncology (WCT).ASCO Pro, 2004, 8163
6[6]Okamoto H, Kudoh H, Nagatomo A, et al. A combination chemotherapy of carboplatin and irinotecan in elderly patients with small cell lung cancer (SCLC). ASCO Pro, 2004, 7212
7[7]FukudaM, Oka M, SoejimaY, etal. Elderly (≥70)smallcell lung cancer (SCLC) chemotherapy: A phase Ⅰ study of carboplatin (CBDCA) and etoposide (VP-16). ASCO Pro,2004, 7217
8[8]Katz AV, Arruda MT, Yamaguchi JY, et al. Comparative retrospective study between brs supportive care (BSC) versus chemotherapy for elderly patients with NSCLC. ASCO Pro, 2004,7355
9[9]Yau T, Asley S, Smith L, et al. Time and chemotherapy treatments trends in the elderly (age 》 70) with lung cancer in a single UK cancer centre. ASCO Pro, 2004, 7128
10[10]The elderly lung cancer vinorelbine Italian study group. Effects of vinorelbine on quality of life and survival of elderly patients with adbanced non-small-cell lung cancer. J Natl Cancer Inst,1999, 91:66
